Gene polymorphisms contributing to hypertension in immunoglobulin A nephropathy
- First Online:
- Cite this article as:
- Shinzawa, M., Yamamoto, R., Nagasawa, Y. et al. Clin Exp Nephrol (2012) 16: 250. doi:10.1007/s10157-011-0553-7
- 207 Downloads
Hypertension, which is affected by genetic and environmental factors, is one of the major risk factors for chronic kidney disease. Identification of the genetic factor contributing to hypertension in patients with chronic kidney disease may potentially refine a therapeutic strategy.
In the present multicenter cross-sectional study, 240 patients were eligible (aged 15–50 years with urinary protein ≥0.25 g/day) out of 429 patients who were diagnosed as having immunoglobulin (Ig) A nephropathy (IgAN) by renal biopsy between 1990 and 2005 and enrolled in our previous study, PREDICT-IgAN. The outcome was hypertension defined as ≥140 and/or ≥90 mmHg of systolic and diastolic blood pressure and/or use of antihypertensives at renal biopsy. We assessed associations between hypertension and 28 polymorphisms with the frequency of minor genotype ≥10% among 100 atherosclerosis-related polymorphisms using the Chi-squared test in dominant and recessive models. We identified polymorphisms associated with hypertension in multivariate logistic regression models.
Baseline characteristics: hypertension 36.3%. Among 28 polymorphisms, the Chi-squared test revealed that CD14 (-159CC vs CT/TT, P = 0.03) and ACE (DD vs DI/II, P = 0.03) were significantly associated with hypertension after Bonferroni correction. Multivariate logistic regression models revealed that CD14 -159CC [vs CT/TT, odds ratio (OR) 3.58 (95% confidence interval (CI) 1.66–7.63)] and ACE DD [vs DI/II, OR 4.41 (95% CI 1.80–10.8), P = 0.001] were independently associated with hypertension.
CD14 C-159T and ACE I/D contributed to hypertension in patients with IgAN.